Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vancomycin + aztreonam or cefazolin + aztreonam
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This designation refers to the active comparator treatment regimens used in pediatric clinical trials for ceftaroline fosamil (Teflaro), specifically for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The regimen consists of either vancomycin (a glycopeptide antibiotic) or cefazolin (a first-generation cephalosporin), with or without the addition of aztreonam (a monobactam). Vancomycin is typically utilized to provide coverage against methicillin-resistant *Staphylococcus aureus* (MRSA), while cefazolin is used for methicillin-susceptible strains. Aztreonam is added when coverage for Gram-negative pathogens is suspected or confirmed. These drugs work by inhibiting bacterial cell wall synthesis through distinct mechanisms: vancomycin binds to the D-alanyl-D-alanine C-terminus of peptidoglycan precursors, while cefazolin and aztreonam inhibit penicillin-binding proteins (PBPs).
- Other names
- Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonamvancomycin + aztreonamcefazolin + aztreonam
02
Targets
PBP (Penicillin-binding protein family)D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on vancomycin + aztreonam or cefazolin + aztreonam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vancomycin + aztreonam or cefazolin + aztreonam.